Protalix BioTherapeutics, Inc. [NYSE: PLX] opened at $0.31 and closed at $0.31 a share within trading session on 10/17/19. That means that the stock dropped by -8.57% compared to the closing price from a day before, when the stock touched $0.29.
Between the start and the closing of the latest trading session, Protalix BioTherapeutics, Inc. [NYSE: PLX] had 3.56 million shares being bought and sold. In the last three months, average trading volumes hovered around 763.43K shares. During the last week, volatility in the share price was set at 22.99%, which placed the metric for the last 30 days at 11.78%. The price of the stock additionally went down to $0.17 during that period and PLX managed to take a rebound to $0.60 in the last 52 weeks.
Protalix BioTherapeutics, Inc. [NYSE:PLX]: Analyst Rating and Earnings
Its stock price has been found in the range of 0.17 to 0.60. This is compared to its latest closing price of $0.31.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Wed 6 Nov (In 19 Days).
Fundamental Analysis of Protalix BioTherapeutics, Inc. [PLX]
Now let’s turn to look at profitability: with a current Operating Margin for Protalix BioTherapeutics, Inc. [PLX] sitting at -62.83 and its Gross Margin at +72.83.
Similarly, its Total Debt to Total Assets stands at 78.46.
What about valuation? This company’s Enterprise Value to EBITDA is -1.83. The Enterprise Value to Sales for this firm is now 0.80, and its Total Debt to Enterprise Value stands at 0.87.
Shifting the focus to workforce efficiency, Protalix BioTherapeutics, Inc. [PLX] earns $186,087 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 10.62 and its Total Asset Turnover is 0.51. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 1.75 and its Current Ratio is 2.09. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Protalix BioTherapeutics, Inc. [PLX] has 148.38M shares outstanding, amounting to a total market cap of $46.74M. Its stock price has been found in the range of 0.17 to 0.60. At its current price, it has moved down by -52.00% from its 52-week high, and it has moved up 69.41% from its 52-week low.
This stock’s Relative Strength Index (RSI) is at 66.65. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Protalix BioTherapeutics, Inc. [PLX] a Reliable Buy?
Shares of Protalix BioTherapeutics, Inc. [PLX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.